Potent pan-HDAC inhibitor
Belinostat is a potent pan-HDAC inhibitor (IC50 = 28 nM). Dose-dependently reduces tumor volume in a rat model of glioblastoma and induces 70% and 28% apoptosis in LN-229 and LN-18 glioma cell lines (IC50 values are 210 nM and 300 nM respectively). In H358 cells, Belinostat dose-dependently reduces cell viability and upregulates amino acids and metabolites of the TCA and urea cycle. Also potently inhibits C4 release from stem cell-derived astrocytes and shows antidepressant activity. Belinostat is brain penetrant.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-160864 |
| Réf. fabricant | 30000421 |
| Nom chimique ou matériau | (2E)-N-Hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-2-propenamide |
| CAS | 866323-14-0 |
| Quantité | 50 mg |
| Cible | Histone Deacetylase Inhibitors |
| Formule moléculaire | C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S |
| Pureté | 98% |
